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Abstract   
Background:  A growing body of research is addressing the role iron plays in Restless Legs 
Syndrome (RLS) pathology and treatment.  Caring for patients suffering from this disease, 
one sees the interruption to, and tangible frustration in, the lives of these patients.  Consensus 
for treatment modalities is incomplete.  The goal of this systematic review of literature is to 
provide a complete picture of the role iron plays in the treatment of RLS.   
 
Methods:  Wide-ranging search of available medical literature.  The keywords: Iron, 
Anemia, Treatment, Restless Legs Syndrome, and Clinical Trial were used in the MEDLINE, 
CINAHL, Evidence-Based Medicine Reviews Multifile and Web of Science databases. 
 
Results:  The search revealed over 25 articles. The literature used in this systematic literature 
review was limited to randomized, double-blind, placebo controlled, studies published after 
2000.  In a majority of these studies iron supplementation was shown to produce a 
statistically significant reduction in patient symptoms.    
 
Conclusion:  Intravenous (IV) iron supplementation combined with sleep hygiene 
counseling, is a potential first-line treatment option for patients with Restless Legs 
Syndrome.  Serum ferritin must be monitored before initiating treatment and quarterly once 
treatment is underway to ensure Hemocromatosis is avoided.   Oral dosage of iron requires 
proper dosage techniques to allow for effective absorption.  Attention to this important factor 
proved lacking in some trials showing no benefit in oral iron supplementation.  More 
information regarding oral and IV iron effectiveness and dosing requirements is necessary for 
iron to become a universally recognized 1st line treatment option.  
 
Keywords:  Iron, Anemia, Treatment, Restless Legs Syndrome, Clinical Trial 
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The Use of Iron in the Treatment of Restless Legs Syndrome 
 
BACKGROUND 
Overview 
“…So great a restlessness and tossing of their members ensue that the diseased are no 
more able to sleep than if they were in a place of greatest torture”.1 This clinical depiction, 
from Sir Thomas Willis in1685 English Medical Literature, describes a condition that has 
since echoed through the adult population only recently gleaning the attention it deserves 
from the medical research community. For 10% of the adult population the symptoms of 
restless legs syndrome (RLS) resonate today.2 Sufferers are mostly over 45 and 
predominantly women.3  Many patients encountered in the clinic describe in great detail, and 
with frustration, an interruption to their night that so consumes them they will choose to 
ignore other more critical health problems preferring to have this specific discomfort 
addressed.4   
Frequently during office visits, patients suffering from RLS also describe the 
repercussions of a poor night’s sleep. The impact of this disease carries through to their day 
to day activities. They are preoccupied with finding relief; once this goal is met the 
improvement in quality of life is appreciated.5  
Through the work of Swedish neurologist Karl Ekbom in 1945, the clinical diagnosis 
of RLS began to take shape. His work entitled Restless Legs was so influential in describing 
this disease clinically, that RLS became known, for a period of time, as Ekbom syndrome.  
The first proposal that iron deficiency played a role in RLS was put forth by Norlander in 
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1954.6 Since 1980, a concerted effort has been made to further the understanding of both, the 
hypothesis that iron plays an integral role in RLS pathology and of, the outcomes of 
treatment with supplemental iron.   
Central iron deficiency has been implicated in the underlying pathology of RLS.  A 
2006 MRI imaging study found brain iron concentrations are lower than average in early 
onset RLS patients.7 Two years later, another MRI imaging survey found multi-regional 
(global) brain iron deficiency in patients with RLS.8 During the last 10 years, through the use 
of Ultrasound B-mode imaging and autopsy, brain iron insufficiency has been implicated in 
RLS.8   
Peripheral iron deficiency, which is considered to be levels of serum ferritin < 50 
ng/ml, figures prominently in patients with RLS.1 The most commonly studied populations 
with RLS include, pregnant women in their third -trimester, those with end stage renal 
disease requiring dialysis, and patients with anemia.9   
There is now a universally recognized set of criteria established by the International 
Restless Legs Study Group (IRLSSG) to aid providers in the clinical diagnosis and 
evaluation of the severity of the patients’ RLS (see table II). In the last 10 years much time 
has been invested in exploring the physiology and treatment of this common condition.    
There are 2 major classifications of RLS – Primary and Secondary. Studies have 
provided many inroads toward understanding both Primary and Secondary RLS.  However, 
today the pathophysiology is not completely understood.   Primary RLS, as compared to 
Secondary etiologies of RLS, typically exhibit varying ages of onset, and rates of disease 
progression.  Patients with Primary RLS are affected earlier in life and have symptoms that 
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progress slowly with age. Primary or Idiopathic RLS is thought to follow an autosomal 
dominant inheritance pattern.10 Secondary RLS is commonly abrupt in onset.  It occurs in 
conjunction with, or due to, iron deficiency. Secondary RLS is most common among 
pregnant, or renal insufficient patients undergoing hemodialysis, or patients suffering blood 
loss.11 These groups experience the greatest resolution of symptoms with iron treatment.12  
This systematic review will answer the clinical question “how affective is treatment 
of RLS with iron?”  This important question will be answered by analyzing the most current 
findings from randomized, double-blind, placebo controlled trials.   
 
PURPOSE OF STUDY 
The best research would address the diversity in the patient population suffering from 
RLS. Different treatment modalities would then be applied to each specific patient 
population. A specific proven treatment regimen could then be fitted to each of the 
subcategories, primary or secondary, under the umbrella of RLS.  This ideal has not been 
completely achieved by a single study up to this point. By compiling the information 
provided by the most appropriate studies, exemplary in their methods, a picture greater than 
the individual sum of its parts emerges. The aim of this project is to concentrate on iron as 
one of the treatment options for patients suffering from RLS. This process includes 
discussion of the safety, the efficacy, the adverse-effects, and dosage forms of iron in the 
treatment of RLS. Once illuminated, treatment recommendations for RLS patients, based on 
the most current and well performed studies, will be made in order to determine the most 
beneficial use of iron supplementation. 
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CLINICAL QUESTION 
The question being proposed is: how effective is treatment of RLS with iron? For this 
condition commonly encountered in the primary care setting, practitioners must have a full 
quiver of treatment options. Each patient must be treated as an individual in order to receive 
the most appropriate plan of care for their specific needs, conditions, and values. Answering 
the question, is iron an effective treatment for patients suffering from RLS will forge another 
treatment modality for clinical use.   
 
METHODS 
This work extends the evolving understanding of RLS by synthesizing the most 
recent information available with an eye toward treating RLS patients with iron 
supplementation.   
 
 
 
SEARCH STRATEGY 
A systematic literature review of studies focusing on iron for the treatment of Restless 
Legs Syndrome was performed using the MEDLINE, CINAHL, Evidence-Based Medicine 
Reviews Multifile and Web of Science databases. The review of literature on this topic was 
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not limited by date so as to include historical writing on this topic and trace the ongoing 
progression of understanding and treatment of RLS.  When considering efficacy of the 
treatment, critically appraised literature was excluded if published before 2000. Only original 
research of the highest standard, randomized double-blind placebo controlled trials, the 
highest standard in research modalities, was included.   
INCLUSIONS / EXCLUSIONS 
Only studies published in the English language were considered. Studies with a focus 
solely on treatments other than iron were excluded. Any study not using randomized, double-
blind, placebo controlled was excluded, although details from articles were used to provide a 
broader historical context.   
RESULTS 
Three studies focusing on the treatment of RLS with IV iron were included in this 
article review. They are all randomized, double-blind, placebo controlled trials with 
populations varying in size, gender, age, and ethnicity. The following is an overview of their 
methods and findings.   
Turning attention first to a multicenter study conducted in Sweden and Germany by 
Grote et al.13 This randomized, double-blind, placebo controlled, study of Intravenous Iron 
Sucrose and Placebo in the Treatment of RLS was published in 2009 by Movement 
Disorders. This corner stone of the studies involving iron in the treatment of RLS utilized the 
largest population size of any randomized, double-blind, placebo controlled studies on the 
treatment results specific to iron.13   
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Following 60 patients, eleven patient visits were performed during the study. There 
were 2 visits each at weeks 2 & 3 for drug infusion as well as subsequent visits at weeks 7, 
11, months 5, 8, and 12. RLS disease severity was assessed using the IRLS at each visit.  
Safety and tolerance of IV iron treatment were evaluated by documentation of adverse 
reactions and by blood samples taken at the intervals listed above. No patients experienced 
changes in their hematology, iron status, and C-reactive protein that required cessation of 
iron treatment or any medical intervention. The paper lists in its findings no adverse affects 
resulting from the study and that the iron sucrose was well tolerated.13 
In total, 30 patients withdrew before the 12 month completion of the study. The 
patient population who withdrew and their stated reasons for withdrawal are a significant part 
of this study’s findings. The single most common reason for discontinuing involvement was 
“lack of efficacy”. Nineteen patients in the placebo group and 5 in the treatment group bowed 
out prematurely for this reason.13 
The methods and scoring values for findings utilized the highest of study standards.  
The outcome was analyzed for the “intention to treat” population (n=60). Missing values 
were replaced applying the last observation carried forward. This process weighs the results 
toward a negative outcome. With the findings weighed towards a negative outcome, the 
positive findings that IRLS is decreased in patients are even more significant. (Treatment: 
1000 mg IV iron sucrose dosed at 200 mg spread evenly over a 3 week period in patients 
with serum ferritin <45nl/l before treatment.  Visually identical placebo: normal saline).13 
Grote et al13 found evidence that IV iron sucrose reduced RLS symptoms both in the 
acute phase of the study (at 7 weeks) and during long term follow up (12-20 weeks). These 
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findings were within a patient population with varying degrees of iron deficiency at initiation 
of iron treatment.  The population was between 18-70 years old,  >10 IRLS, had the four 
cardinal RLS diagnostic criteria, and had serum ferritin >45 nl/l.  Median IRLS score 
decreased from 27 to 7 (week 11) after iron sucrose and from 26 to 17 after placebo. The 
other scores at weeks 7, 12, 20 and 12 months, found this treatment modality provided 
significant long term RLS symptom control.13   
Complementing this body of work is a smaller population randomized, double-blind, 
placebo controlled study performed in 2008 and published in Sleep Medicine in 2009. This 
study looked at the efficacy of oral iron in patients with RLS and a low-normal ferritin. 
Wang et al14 utilized the Madigan Army Medical Center as a study location. A patient 
population was generated from current patients at the facility who met diagnostic criteria for 
RLS (IRLS >10). The group was further screened and only patients with a ferritin level of 
15-75 ng/l were included. 18 patients remained, 11 were randomized to iron therapy and 7 to 
placebo.14   
   Patients were followed over 12 weeks. The treatment group was administered ferrous 
sulfate 325mg orally, twice daily. The placebo group was given an appearance matched 
placebo on the same schedule. All patients were also asked to take vitamin C concurrently 
(100 mg. PO).  This is common, as an acidic environment in the GI tract facilitates 
absorption of iron taken orally. Patients were followed at 6 and 12 weeks during which they 
were asked to complete IRLS scoring questionnaires. They were also monitored for adverse 
events.  There were no events requiring cessation of iron treatment or medical intervention 
during the course of the trial.14   
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The findings of this study demonstrate statistically significant improvements in RLS 
symptoms using oral iron therapy in patients with low-normal serum ferritin levels. The 
mean baseline IRLS scores for iron and placebo groups were 24.8 and 23. Mean decreases in 
IRLS after 12 weeks for the 325 mg BID iron group was 10.3 and in the placebo 1.14. (p- 
score = .00045) 
The outcome of Davis et al2 randomized, double-blind, placebo controlled study 
conducted in 1999, and published in European Neurology in 2000, reached a different result 
than the previously discussed studies.  It concluded there were no significant differences in 
outcome between their iron treatment and placebo groups.  In this study, conducted by the 
department of neurology at the University of Iowa, participants were followed at University 
of Iowa Hospitals and Clinics Iowa City, Iowa.  The patient population included 2 groups of 
14 patients administered either 325mg ferrous sulfate or placebo, orally, twice daily (PO, 
BID).2 
Patients included in the study had to have “symptomatic RLS”, and be under 
treatment for RLS at the time of enrollment.  Symptomatic RLS was not defined by the 
authors of the paper. Because the patients were selected based on the diagnosis of RLS in 
their medical record one assumes that symptomatic, in this instance, means positive on each 
of the diagnostic 4 RLS criteria.  Patients were included regardless of other potential causes 
of RLS, such as neuropathy.  Potential participants were excluded only if they had a history 
of treatment for RLS with iron or if they were “anemic” (hemoglobin <10).2 
  Medical history, physical examination, and adverse event reporting were all 
performed at time of enrollment and at weeks 2,4,14, & 26.  There were no events requiring 
cessation of iron treatment or medical intervention during the course of the trial. Adverse 
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events were noted in 9 patients taking iron sulfate. There was no discussion associating the 
adverse events directly with iron supplementation. Adverse events include: 
nausea/constipation (5 patients), dark colored stools (3 patients), tooth discoloration (2 
patients) vertebral fracture (1 patient), worsening of RLS symptoms (1 patient) & bladder 
spasms. The vertebral fracture was determined to be unrelated by the authors of the study. 2  
   The primary outcome measure was the dichotomous variable of improvement or no 
improvement in average quality of sleep over weeks 13-14. These findings were compared to 
baseline established in the 2 weeks previous to the study beginning. Patients documented the 
severity of their RLS on a 100mm visual analog scale ranging from “slept very well” to 
“impossible to sleep”. At week 14 the question was changed to how does RLS affect your 
life; the same scale was employed with the two poles being “does not affect my life” and 
“makes my life miserable”.2 
 
DISCUSSION  
 Systematically reviewing the results of randomized, double-blind, placebo contolled 
iron trials within the last 10 years, contrasting their findings, methods, and patient 
population, informs a consideration of iron’s effectiveness in RLS treatment. In their trials 
Grote et al13 and Wang et al14 concluded that iron supplementation resulted in statistically 
significant improvement in RLS symptoms. The study by Davis et al2 found that “iron sulfate 
does not appear to be a successful empiric treatment for RLS”.2 
Davis et al2 took no steps to improve the iron absorption in the treatment group, 
ferrous sulfate 325mg PO BID. The widely accepted understanding concerning the difficulty 
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of absorbing oral iron supplements was not addressed in this study. How to maximize the 
absorption of oral iron supplements is integral to any discussion of oral iron therapy. An 
acidic gastrointestinal environment is necessary for the absorption of oral iron agents.   
Comparing the success between 2 separate studies with identical dosing of ferrous sulfate 
325mg PO BID only patients taking concurrent vitamin C 100mg appreciated a significant 
improvement in RLS symptoms. This adds more evidence and support to the belief that oral 
iron’s effectiveness is integrally linked to proper dosing technique.   
It is Wang et al14 whose findings supported the use of oral iron, who took into account 
the variability in absorption. Utilizing ferrous sulfate 350mg PO BID and facilitating a 
gastrointestinal environment suited to absorption of iron, an acidic environment via vitamin 
C 100 mg, produced statistically significant results in support of iron in the treatment of 
RLS.14   
Turning to treatment with IV iron sucrose, Grote et al13 conducted an exemplary and 
flawless study with results supporting IV iron treatment in RLS patients. Their numbers are 
telling in their strong implication that relevant RLS symptoms were far less frequent in 
patients receiving iron sucrose (p=0.0006).13   
Iron sucrose is the preferred form of iron for IV use. This form is the most studied 
and utilized IV iron supplement in current literature.12 It is associated with the least negative 
adverse affects of all available IV iron forms.     
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CONCLUSION 
Before initiating iron therapy the IRLS scale (see figure I) should be used to diagnose 
and document a patient’s RLS severity.15 This tool also allows a provider to monitor 
treatment outcomes and tailor a treatment plan for each patient’s specific needs. In RLS 
patients serum transferrin saturation and ferritin levels should be monitored.16, 17 Patients with 
a history of iron deficiency or low serum iron parameters should undergo evaluation for the 
underlying iron deficiency ideology. Patients who have histories suggestive of 
hemochromatosis, iron overload, elevated pre-treatment transferrin saturation or serum 
ferritin levels should undergo evaluation to determine the cause of these abnormalities before 
they are treated with iron. These populations are at the highest risk for serious side effects 
associated with iron treatment. In all persons with RLS treated with iron, serum iron 
parameters should be re-measured at least quarterly. Iron treatment for patients with RLS 
must be combined with counseling regarding sleep hygiene.1   
Iron appears to be an appropriate treatment for patients in the following categories: 
pregnant / dialysis / iron deficient patients (ferritin <45).13, 14 1000mg IV iron sucrose dosed 
at 200 mg over for 3 weeks or oral iron (ferrous sulfate) 325mg BID concurrently with 100 
mg vitamin C PO were both shown to be successful in decreasing RLS symptom severity in a 
majority of the patients as opposed to placebo group.2, 13, 14 
Further studies are warranted before Iron will be universally accepted as a first line 
treatment. The next generation of studies must take into account target patient groups, dosing 
type, dosing intervals, and comparison with other treatment modalities. To this point no 
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comparison study has been conducted directly comparing the two preferred treatment 
methods - dopamine agonists and iron.   
Grote et al13 did state the relief of symptoms with their treatment was in comparable 
order with current clinical trials supporting dopamine agonists.13  With dopamine agonists 
and iron commonly being prescribed for this condition, and both resulting in symptom 
improvement, comparing the effectiveness would be a logical next step in forming a 
complete consensus for a particular treatment modality.   
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TABLES 
 
Table I 
International Restless Legs Rating Scale 
Have the patient rate his/her symptoms for the following ten questions. 
The patient and not the examiner should make the ratings, but the examiner should be 
available to clarify any misunderstandings the patient may have about the questions. 
The examiner should mark the patient's answers on the form. 
In the past week… In the past week… 
(1) Overall, how would you rate the RLS 
discomfort in your legs or arms  
 
_ (4) Very severe _ (3) Severe _ (2) 
Moderate_ (1) Mild_ (0) None 
(6) How severe was your RLS as a whole?  
 
_ (4) Very severe_ (3) Severe_ (2) 
Moderate_ (1) Mild_ (0) None 
In the past week…  
(2) Overall, how would you rate the need to 
move around because of your RLS 
symptoms?  
 
_ (4) Very severe_ (3) Severe_ (2) 
Moderate_ (1) Mild_ (0) None 
In the past week… 
(2) Overall, how would you rate the need to 
move around because of your RLS 
symptoms? (7) How often did you get RLS 
symptoms? (7) How often did you get RLS 
symptoms? 
 
_ (4) Very severe_ (3) Severe_ (2) 
Moderate_ (1) Mild_ (0) None 
In the past week… 
(3) Overall, how much relief of your RLS 
arm or leg discomfort did you get from 
moving around? 
 
_ (4) Very severe_ (3) Severe_ (2) 
In the past week… 
8) When you had RLS symptoms, how 
severe were they on average? 
 
_ (4) Very severe_ (3) Severe_ (2) 
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Moderate_ (1) Mild_ (0) None Moderate_ (1) Mild_ (0) None 
In the past week… 
(4) How severe was your sleep disturbance 
due to your RLS symptoms? (9) Overall, 
how severe was the impact of your RLS 
symptoms on your ability to carry out 
your daily affairs, for example 
_ (4) Very severe_ (3) Severe_ (2) 
Moderate_ (1) Mild_ (0) None  
In the past week… 
(9) Overall, how severe was the impact of 
your RLS symptoms on your ability to carry 
out your daily affairs, for example  
 
_ (4) Very severe_ (3) Severe_ (2) 
Moderate_ (1) Mild_ (0) None 
In the past week… 
 
(5) How severe was your tiredness or 
sleepiness during the day due to your RLS 
symptoms?  
 
_ (4) Very severe_ (3) Severe_ (2) 
Moderate_ (1) Mild_ (0) None 
In the past week… 
 
(10) How severe was your mood disturbance 
due to your RLS symptoms - for example 
angry, depressed, sad, anxious or irritable? 
 
_ (4) Very severe_ (3) Severe_ (2) 
Moderate_ (1) Mild_ (0) None 
Sum of scores = 
Scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); 
Very severe (score 31-40) 
1. Answers for this IRLS are scored from 4 for the first (top) answer (usually ‘very severe’) 
to 0 for the last answer (usually none). All items are scored. The sum of the item scores 
serves as the scale score. 
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Table II 
Summary Matrix 
Author/  
Journal 
Yr.  
published 
Patients/  
Population 
Intervention Comparison Outcome(s) Study type 
Grote MD, 
Leissner MD, 
Hedner MD, 
Ulfberg MD. 
 
Movement 
Disorders, Vol, 
24. No. 10, 
2009  
 pp. 1445-1452 
2009  60 patients 
with 
primary 
RLS 
recruited 
from a 
cohort of 
231 patients 
Intravenous 
Iron Sucrose 
Placebo IV Iron 
sucrose 
reduced 
RLS 
symptoms 
both in the 
acute phase 
and during 
long term 
follow up in 
patients with 
variable 
degree of 
iron 
deficiency. 
Randomized, 
Double-Blind, 
Placebo 
Controlled, 
Multi-Center 
Study. 
 
Utilized  
Wang, 
O’Reilly, 
Venkataraman,
Mysliwiec M, 
Mysliwiec A, 
 
Sleep Medicine 
Vol. 10, 2009 
pp. 973-975 
2009 18 Oral Iron 
suppliments 
Placebo IRLS scores 
decreased 
more 
significantly 
in the 
treatment vs 
placebo 
group.   
Nonsignifica
nt trend 
towards 
improved 
quality of 
life in the 
patients 
treated 
(p=0.07) 
Institutional 
review board 
approved, 
Randomized, 
Double-Blind, 
Placebo 
Controlled, 
Single 
location. 
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Davis, Rajput 
A, Rajput M,  
European 
Nurology 
Vol 43, 2000 
pp. 70-75 
2000 28 patients Ferrous 
sulfate 325 
mg b.i.d 
Placebo Ferrous 
Sulfate 325 
BID does 
not appear 
to be 
affective 
empiric 
treatment 
for restless 
legs 
syndrome.   
Randomized, 
Double-Blind, 
Placebo-
Controlled 
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FIGURES 
 
Figure I: Sleep cycle, Restless Legs Syndrome 
 
 
 
 
 
 
 
 
 
 
  
